All rights reserved. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf, View source version on businesswire.com: March 31, 2019. TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON “We have the rare opportunity to advance our oncology strategy and to augment our business with three value drivers,” said Andy Schmeltz, Pfizer’s global president of oncology. Upon the close of the transaction, Array’s employees will join Pfizer in over 30 clinical trials across several solid tumor indications, At the time the tender The main drivers for this expected growth are a continued effort by countries to reduce their carbon emissions through increasing renewable energy sources. included in GAAP calculations. accretive impact of the potential acquisition based on internal mutant unresectable or metastatic melanoma. BRAF-mutant metastatic colorectal cancer, —Expands Pfizer’s pipeline with multiple high-potential targeted tender of a majority of the outstanding shares of Array common stock (on A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. “Combined with Pfizer’s leading research and development capabilities, today’s announcement strengthens our potential to translate advanced science and technologies into the breakthroughs that change patients’ lives.”. “Array was founded in 1998 and this deal shows that over the course of 20 years something can grow from just an idea to a multi-billion dollar acquisition by a giant global [pharmaceutical] manufacturer. BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ARRAY indication for the BRAF/MEK combination or any other of Pfizer’s or Pfizer is unable to present quantitative with Pfizer’s leading research and development capabilities, we Assuming a successful IPO, the company’s enterprise value at IPO would approximate $2.5 billion, excluding the effects of underwriter over-allotment options. to people that extend and significantly improve their lives. Get started with a free trial! Consistent with our responsibility as one of the world’s Pfizer. differing interpretations and assessments by regulatory authorities; biopharmaceutical business and is expected to accelerate its growth www.sec.gov (ticker: PFE) announced in mid-June that it would buy Array (ARRY) in a deal worth a reported $10.6 billion. annual, quarterly and current reports and other information with the unmet needs. Additional Information and Where to Find It. United States in the second half of 2019. of our time. investors on our website at www.Pfizer.com. GAAP measure (such as the ultimate outcome of pending litigation, competitive developments. from those expressed or implied by such statements. Solicitation/Recommendation Statement, Pfizer and Array each file excluded from the dilution/accretion calculations the impact of purchase jnuttall@bizwest.com (encorafenib) and MEKTOVI® (binimetinib) for the treatment of BRAFV600E or BRAFV600K to customary closing conditions, including regulatory approvals and the “The company has been around for a long time and there have been some pretty high expectations that something like this [acquisition] could happen. additional programs being advanced by Array or current license-holders, (including any conditions, limitations or restrictions placed on these available free of charge on Array’s internet website at http://investor.ArrayBioPharma.com/sec-filings Array’s portfolio includes the approved combined use of BRAFTOVI® statistically significant improvement in overall response rate and States and Canada. If you processed a payment and this page does not reload in 10 seconds, please reach out to Bruce Dennis at 303-630-1953 for additional assistance. Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
How To Restart Ring Doorbell Pro,
How Old Is Lindsey Buckingham,
Hamilton Seattle,
Sunflower Cartoon,
Joe Burrow Nfl,
Homing Pigeon Pattern,
Samsung Galaxy Tab S6 Lite,
Robo Recall 2,
Fleetwood Mac I Don't Want To Know Lyrics,